This study was undertaken to evaluate the antidiabetic effect of edible seaweeds Sargassum wightii and Ulva fasciata with an objective to establish these seaweeds as add-on therapy for controlling diabetes. The ethyl acetate extract of Sargassum wightii (EAS) and Ulva fasciata (EAU) at 100 and 200 mg/kg dose was examined for antidiabetic activity in the high fat diet and multi-low-dose streptozotocin induced type 2 diabetic mice. Plasma glucose, oral glucose tolerance test [OGTT], lipid profile, liver and skeletal muscle glycogen content, triglycerides, superoxide dismutase [SOD], body and organ weight was estimated at the end of the study.
. These seaweed fibers have been found to produce hypocholesterolemic and hypolipidemic responses as it tend to reduce cholesterol absorption in the gut 8 . In addition, fat contents of most of the seaweeds are very low (<2%) and these are rich source of poly unsaturated fatty acids [PUFA] Spatoglossum asperum and Caulerpa racemosa in rats 11 . Some diabetologists suggest that alpha-glucosidase inhibitors are a costeffective means to prevent the progression of diabetes as this enzyme reduces the absorption of glucose from the gut itself.
Seaweeds stand as a unique source of natural alpha-glucosidase inhibitors from nature as per some of the previous studies 12, 13 .
Recently some researchers revealed that fucoxanthin, a type of carotenoid found abundantly in edible brown seaweeds are having good hypoglycemic effect 14 .
Marine macro algae offer a great opportunity to satisfy the food and nutritional requirement for rectifying and controlling diabetes. The strong evidence in support of this contention is that, Japanese diet contains nearly 10-15% marine macro algae and the prevalence of diabetes and metabolic syndrome in this country is less compared to western countries 15 . Incorporation of seaweeds into a balanced diet could definitely help in minimizing and reducing instances of diabetes to a greater extent.
Sargassum wightii is dark brown seaweed which is used as raw material for the production of sodium alginate. Traditionally this seaweed is used to treat goiter in Chinese medicine 16 . In addition to that, this seaweed has been proven to have promising antiAlzheimer 16  Whereas the autonomic profile includes observing for the defecation and urination of the animals.
Experimental animals and induction of type 2 diabetes mellitus
Swiss albino male mice weighing 22-27 g were maintained in our animal house for this specific study. All animals were housed in standard cages (48x35x22 cm) at room temperature (20±2°C) with artificial light from 7.00 am to 7.00 pm, and provided with normal chow pellet food [Rayan's Ltd, Hyderabad, India] and water ad libitum; ambient relative humidity was maintained at 55-60%. After acclimation in our laboratory for one week, selected 35 numbers of male albino mice were divided into 7 experimental groups, each group containing five animals in it to receive the following treatments: Group 1 were normal non diabetic mice which received normal saline only throughout the treatment period. Group 2 were diabetic mice which were administered with 1% sodium carboxy methyl cellulose (CMC) orally. Group 3 and 4 consist of diabetic mice and were orally administered 100 and 200 mg/kg EAS respectively. Groups 5 and 6 consist of diabetic mice and were orally administered 100 and 200 mg/kg of EAU respectively. Group 7 were diabetic mice which received 10 mg/kg gliclazide orally. days. Prior to each study, the animals were subjected to fasting for 12 h with free access to R.O. water.
Collection of blood and determination of plasma parameters
Animals were fasted overnight for a period of 12 h. Blood (0.5 ml)
was withdrawn via the retro-orbital sinus under mild ether anaesthesia and was collected in micro tubes previously filled with 10% EDTA solution (20 µl of 10% EDTA/ ml of blood). The micro tubes were centrifuged at 4000 rpm at 4°C for 20 min to obtain clear plasma. The plasma was analyzed for plasma glucose, triglyceride (TG), total cholesterol (TC) and high density lipoprotein (HDL) in auto-analyzer using respective diagnostic kits. Very low density lipoprotein (VLDL) and low density lipoprotein (LDL) were calculated as per Friedwald's equation:
VLDL= TG/5; LDL= TC-VLDL-HDL
Oral glucose tolerance test (OGTT)
OGTT 32-37 was performed in overnight fasted mice. The animals were however allowed to drink water and the respective drugs were administered at the regular time to different treatment groups.
Glucose (2 g/kg) was fed to each animal 10 min after collecting the blood samples which was taken as reference (0 min). Exactly 0.1 ml of blood was withdrawn from the retro orbital route of each mouse under mild ether anaesthesia at 30, 60 and 120 min after the glucose load. The plasma obtained was analyzed for glucose.
Organ and Skeletal muscle weight
Mice were sacrificed by over anesthesia (diethyl ether) at the end of the study period and then liver, pancreas and skeletal muscle (Gastrocnemius muscle from left and right legs) were isolated. The wet weight was taken immediately after drying on a blotting paper.
Estimation of liver and skeletal muscle TG
Frozen liver (5 mg) and skeletal muscle (15 mg) were used for TG extraction 38 . Each frozen tissue was added to 0.3 ml heptaneisopropanol-tween mixture (3: 2: 0.01 by volume) and homogenized.
This homogenate was centrifuged at 1500xg at 4°C for 15 min.
Supernatants (upper phase contained extracted TG) were collected and evaporated with vacuum centrifuge. The TG content was estimated by spectrophotometry with commercial kit.
Estimation of liver and skeletal muscle Superoxide Dismutase (SOD)
Mice were sacrificed using anesthesia (diethyl ether) at the end of the study period. The gastrocnemious muscle and liver were quickly 
Liver histopathology studies
Part of the liver from the left lobe of each sacrificed mice was harvested and fixed in 10% neutral buffered formalin, while the remaining tissue were stored at −80°C for further analysis. For histological analysis, tissue sections were embedded in paraffin.
Further these tissue sections were de-paraffinized, stained with haematoxylin-eosin (H&E) and examined under light microscopy at 100X magnifications 42,43 .
Statistical analysis
Results were expressed as mean ± SEM. Data were analyzed with
One-way Analysis of Variance (ANOVA), followed by Tukey's multiple comparison tests. The level of significance was set at p< 0.05.
Results

Toxicity study of the seaweed extracts as per OECD guidelines 423
The toxicity of those extracts was recorded after single oral administration to the animals. During the observation period, no abnormal behavior and mortality were reported in the animals under study by using any of the seaweed extract and as such the extracts were found to be safe at the dose level of 2000 mg/kg body weight.
Plasma glucose
The effects of EAS and EAU treatment on plasma glucose of diabetic mice are presented in figure 1. Both EAS 200 and 100 mg/kg treatment showed significant (p<0.001 and p<0.05 respectively) reduction in plasma glucose whereas EAU showed significant (p<0.01) reduction in plasma glucose only at the higher dose (200 mg/kg).
Plasma lipids
The effect of EAS and EAU treatment on plasma lipid profile of diabetic mice is illustrated in 
OGTT
Impaired glucose tolerance is reflected in a larger incremental area under the curve (AUC) of the plasma glucose OGTT curve. The AUC of the plasma glucose was significantly (p<0.001) higher in case of diabetic control. However, the AUC of OGTT curve was significantly (p<0.001) attenuated in both EAS and EAU treated animals at both doses (100 and 200 mg/kg).The extent of reduction was also higher in Gli 10 mg/kg treated mice (p<0.001). The AUC of the plasma glucose disappearance curve is shown in figure 2.
Body weight
At the end of the treatment, body weight gain was estimated for all groups. It was found that diabetic mice significantly (p<0.001) lose their body weight as compared to normal mice at the end of the study period. However, EAS treated animals showed significant (p<0.001 at 200 mg/kg and p<0.05 at 100 mg/kg) gain in body weight compared to diabetic mice. EAU showed significant (p< 0.01) improvement in body weight only at the higher doses. The result is depicted in table 2. 
Liver and Skeletal muscle (Gastrocnemius muscle) TG
The TG of liver and skeletal muscle recorded after the treatment provided to the mice is depicted in table 3. Both EAS and EAU at 200 mg/kg showed significant (p<0.001) reduction in liver TG. EAS showed significant (p<0.01) reduction in liver TG at the lower doses whereas EAU didn't show any significant result at this dose. In case of skeletal muscle TG, EAS and EAU showed significant (p<0.01 and p<0.05 respectively) reduction at the higher doses but didn't show any significant result at lower doses.
Liver and Skeletal muscle (Gastrocnemius muscle) SOD
SOD is significantly (p<0.01) lower in the diabetic control group than that of the normal group in case of skeletal muscle SOD estimation.
But EAS and EAU at higher dose treatment could bring significant (p<0.05) improvement in this antioxidant level compared to standard drug in case of skeletal muscle SOD estimation. However, no significant result was found in case of liver SOD antioxidant activity.
Result is presented in table 3. Both EAS and EAU showed significant (p<0.05) increase in glycogen content of skeletal muscle at the higher dose treated groups. The detail result is depicted in table 3.
Liver and skeletal muscle (Gastrocnemius
Liver histopathology
Due to HFD, the liver shows extensive microvesicular and macrovesicular fatty changes with fatty cyst formation. In diabetic control group, HFD causes destruction of hepatocytes/ parenchyma cells and results in liver steatosis. EAS and EAU treated groups show less number of fatty changes with the least number of fatty cyst in their liver and showed hepatoprotective effect on liver cells. The detailed results of liver histopathology study are depicted in figure 3 (A, B, C, D, E, F, G). . Therefore, HFD followed by MLDS induced diabetes in Swiss albino male mice was chosen for our study that would closely mimic the natural history of the disease 46 . MLDS injection (40mg/kg body weight) after feeding HFD has shown significant abnormalities in blood glucose, lipid profile, OGTT, body weight and organ weight in diabetic animals. Antioxidant status, TG, glycogen level in liver and skeletal muscle was very low in diabetic animals as compared to other treatment groups.
In this study, both seaweeds showed the significant decrease in plasma glucose at the end of the treatment which was similar to these kinds of previously done studies 47, 48 . . This is because insulin has a role in inhibiting the hormone sensitive lipase and activating lipoprotein lipase. Therefore, in diabetic individuals, the transportation of free fatty acids from adipose tissues is increased and as a result of which total TG levels of serum are elevated 50 . Seaweed extracts treatment resulted in lower levels of TG and TC. EAS and EAU at 200 mg/kg could bring about significant (p<0.05) change in plasma HDL and LDL level.
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Only small but not statistically significant changes were seen in VLDL levels. These results were somewhat similar to earlier studies, which reported decreased lipid levels with diets containing gelforming fiber 6, 51 and seaweeds supplement 52 .
OGTT is an easy diagnostic test used extensively for the diagnosis of type 2 diabetes. This test displays the competence of the diabetic individual to effectively utilize glucose after a meal or oral glucose load. The OGTT or meal tolerance test resembles the glucose and insulin dynamics of physiological conditions closely. Impaired glucose tolerance is reflected in a larger incremental AUC of the plasma glucose disappearance curve. Results of OGTT revealed that AUC of the plasma glucose was significantly (p<0.001) higher in case of diabetic control. However, the AUC of OGTT curve was significantly (p<0.001) attenuated in both EAS and EAU treated animals at both low and high doses.
Uncontrolled diabetes is evidenced by constant high blood glucose levels and can cause of weight loss in our body. This may be because of insufficient amounts of insulin made by the pancreas.
When there isn't enough insulin around, glucose stays in blood and can't get into the cells to be used for energy. The body needs fuel from somewhere, so in the absence of glucose, it starts to burn fat and muscle proteins. This mechanism of muscle wasting can be attributed to be the main reason of weight loss in diabetics 53 . It was found that diabetic mice significantly (p<0.001) lose their body weight as compared to normal mice at the end of the study period.
However, both EAS and EAU treated animals showed significant It is known that the quantity of TG in the skeletal muscle and liver is significantly increased in uncontrolled diabetes mellitus, which results from increased free fatty acids levels in the plasma. During a study, fucoxanthin rich brown seaweed extract was evaluated to find out its usefulness as nutraceutical, hypolipidemic and as an antiobesity agent in C57BL/6J mice. The results of this study indicated that the extract reduced hepatic TG significantly 57 . Our findings also agree with this result.
During diabetic state, increased generation of ROS occur and cause an imbalance between the oxidant and antioxidant status 58 .
Sustained hyperglycemia is the main cause of increased ROS generation in diabetes 59 . This might be the result of suppression of beta-cell proliferation and inhibition of insulin gene transcription 60 
